SCD therapy — Topline data
2027
We anticipate reporting topline clinical trial results and, assuming a successful trial outcome, submission of a Pre-market Approval ("PMA") application in 2027.Source filing
ICU biotech catalysts & pipeline
SEASTAR MEDICAL HOLDING CORP · Data as of 2026-10-25
Upcoming catalysts
SCD therapy — NDA/BLA submission
Late 2027
Completion of enrollment is anticipated around year end or into the first quarter of 2027, which would enable a PMA application to the FDA near the end of 2027, pending a positive outcome of the trial.Source filing